No matches

38 search results for: COPD

Content temporarily unavailable

ERS 2024 | Targeting IL-33 in COPD: Exploring New Frontiers for COPD Management

Professors Klaus Rabe, Paola Rogliani, and Dr. Stephanie Christenson explore the complexity of inflammatory pathways and phenotypes in COPD. They provide insights into the genetic association of IL-33 with COPD, discuss preclinical findings, and review ongoing clinical research targeting IL-33 in COPD.

Content temporarily unavailable

ADVENT at ERS 2026

Join Sanofi and Regeneron for four educational symposia on asthma, COPD, and the unified airway.

Content temporarily unavailable

World Lung Day 2024

September 25th marks this year’s observance and celebration of World Lung Day!

Content temporarily unavailable

ERS 2024 | The Role of IL-33 in COPD Patho and Its Impact on Disease Remodeling

Professor Paola Rogliani examines the role of IL-33 in the pathophysiology of COPD, focusing on its contribution to airway inflammation, remodeling, and disease progression.

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: SwedenChange country/region